- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06285916
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (NuMom)
February 22, 2024 updated by: Gerbera Therapeutics, Inc.
A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine:
- How well NORA520 is tolerated and what side effects it may cause
- If NORA520 reduces depressive symptoms in subjects with severe PPD
- The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken
- In a subset of subjects, the amount of NORA520 in breastmilk at various times after taking it to determine if and how much NORA520 can pass into breastmilk Participate in this study will be randomly assigned to one of 3 different groups. All subjects will take the study drug for 3 days.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trial Team
- Phone Number: +886-2-8501-2609
- Email: clinicaltrial@gerberarx.com
Study Locations
-
-
California
-
Canoga Park, California, United States, 91304
- Gerbera site
-
-
Florida
-
Miami Gardens, Florida, United States, 33014
- Gerbera sites
-
Orlando, Florida, United States, 32807
- Gerbera site
-
Saint Petersburg, Florida, United States, 33607
- Gerbera site
-
-
Texas
-
League City, Texas, United States, 77573
- Gerbera site
-
Richardson, Texas, United States, 75080
- Gerbera site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Are willing and able to provide signed informed consent to participate in the study and to comply with all study procedures and scheduled visits
- Are an adult female between 18 and 45 years of age, inclusive;
- Have either ceased lactating at Screening, or if still lactating or actively breastfeeding at Screening, agree to temporarily cease giving breastmilk to their infant(s) from just prior to first dose of study drug on Day 1 through Day 14;
- Have a negative pregnancy test at Screening and Day 1 (prior to dosing);
- Have had a depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery
- Are ≤9 months postpartum at Screening.
Key Exclusion Criteria:
- Have a history or current diagnosis or current treatment of bipolar disorder, schizophrenia, or schizoaffective disorder;
- Have had recorded treatment failure of ≥2 different antidepressant classes (e.g., SSRI, SNRI) in the current or previous episode;
- Are currently experiencing active psychosis per Investigator assessment, or are taking typical or atypical antipsychotic medication;
- Have a history of suicidal behavior within 2 years;
- Have a history or current diagnosis of sleep apnea or narcolepsy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Oral Placebo tablets for 3 days
|
Experimental: NORA520 Dose 1
|
Oral NORA520 tablets Dose 1 for 3 days
|
Experimental: NORA520 Dose 2
|
Oral NORA520 tablets Dose 2 for 3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, severity, and causality of AEs, SAEs, and AESIs
Time Frame: Up to Day 30
|
Adverse events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)
|
Up to Day 30
|
Change from baseline in HAM-D17 total score compared to placebo
Time Frame: Baseline to Day 4
|
The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss.
|
Baseline to Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in HAM-D17 total score
Time Frame: Baseline to Days 8 and 30
|
The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss.
|
Baseline to Days 8 and 30
|
HAM-D17 response
Time Frame: Baseline to Days 4, 8, and 30
|
Defined as having a 50% or greater reduction from baseline in HAM-D17 total score
|
Baseline to Days 4, 8, and 30
|
HAM-D17 remission
Time Frame: Baseline to Days 4, 8, and 30
|
Defined as having a HAM-D17 total score ≤7
|
Baseline to Days 4, 8, and 30
|
Change from baseline in HAM-D17 subscale and individual item scores
Time Frame: Baseline to Days 4, 8, and 30
|
The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss.
|
Baseline to Days 4, 8, and 30
|
Change from baseline in Clinical Global Impression - Severity (CGI-S) score
Time Frame: Baseline to Days 4, 8, and 30
|
The CGI-S scale is a 7-point scale that requires the Investigator to assess how mentally ill is the patient at this time
|
Baseline to Days 4, 8, and 30
|
Clinical Global Impression - Improvement (CGI-I) scale positive response
Time Frame: Baseline to Days 4, 8, and 30
|
The CGI-I scale is a 7-point scale that requires the Investigator to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of study drug treatment
|
Baseline to Days 4, 8, and 30
|
Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Time Frame: Baseline to Days 4, 8, and 30
|
The MADRS contains 10 individual items related to the following symptoms: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.
|
Baseline to Days 4, 8, and 30
|
Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score
Time Frame: Baseline to Days 4, 8, and 30
|
The HAM-A contains 14 individual ratings related to the following symptoms: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic (muscular), somatic (sensory), cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview.
|
Baseline to Days 4, 8, and 30
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) total score
Time Frame: Baseline to Days 8 and 30
|
The Edinburgh Postnatal Depression Scale (EPDS) is a set of 10 screening questions.
The total score ranges from 0 to 30, with higher scores indicating more severe depression.
|
Baseline to Days 8 and 30
|
Number of patients who start any new antidepressant or anti-anxiety medication
Time Frame: After Day 8 assessments through Day 30
|
After Day 8 assessments through Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
February 1, 2026
Study Completion (Estimated)
March 1, 2026
Study Registration Dates
First Submitted
February 17, 2024
First Submitted That Met QC Criteria
February 22, 2024
First Posted (Estimated)
February 29, 2024
Study Record Updates
Last Update Posted (Estimated)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NORA520-PT-US-1a
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Depression
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
-
British Columbia Children's HospitalActive, not recruiting
-
University of RochesterMae Stone Goode FoundationCompletedPostpartum Depression | Postpartum AnxietyUnited States
-
Hacettepe UniversityCompletedQuality of Life | Postpartum Depression | Nursing Caries | Nurse's Role | Postpartum Disorder | Postpartum AnxietyTurkey
Clinical Trials on NORA520 Dose 1
-
Medy-ToxCompletedLateral Canthal Lines | Glabellar LinesUnited States, Russian Federation, Germany, Canada, Belgium, United Kingdom
-
Zensun Sci. & Tech. Co., Ltd.Zensun USA Inc.CompletedChronic Heart FailureUnited States
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Oryn Therapeutics, LLCCompletedRheumatoid ArthritisUnited States
-
Loyola UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Renibus Therapeutics, Inc.CompletedAKIUnited States, Australia, Canada
-
Aronora, Inc.CompletedThrombosis | End Stage Renal DiseaseUnited States
-
Institute of Medical Biology, Chinese Academy of...Guangxi Center for Disease Control and PreventionCompleted
-
Pharnext SACompletedPhase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT)Charcot-Marie-Tooth Disease Type 1AUnited States, United Kingdom, Belgium, Canada, France, Netherlands, Spain, Germany